Detalhe da pesquisa
1.
Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
J Clin Pharmacol
; 57(4): 484-492, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27558232
2.
Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.
Cancer Chemother Pharmacol
; 78(4): 847-53, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27586967